Speaking on the above topic is Dr Tony D’Amore, Vice President, Process Development, Sanofi Pasteur, Canada. He will be presenting at Biologic Manufacturing World Asia 2012, part of a series of conferences in the 5th Annual BioPharma Asia Convention 2012, held on 19-22 March at Marina Bay Sands, Singapore.
In his role as Vice President, BioProcess R&D NA at sanofi pasteur, Dr. D’Amore provides leadership to a Division of over 100 people and contributes to the growth and profitability of the Company through the overall direction, administration and management of all activities related to leveraging company research capabilities and intellectual property in the development of new or improved products. Dr. D’Amore received his Ph.D. in Biochemistry from the University of Windsor. He joined sanofi pasteur in 1994 (then Connaught Laboratories) as a Purification Scientist. Since 2001, he has been the Vice-President of Process Development responsible for process development and clinical material manufacture. During this time, he also obtained his MBA from Wilfrid Laurier University.
Dr D’Amore will be speaking on the following:
Managing the needs of vaccine manufacturing in Asia for improved manufacturing operations
1. Assessing the opportunities and challenges facing the vaccine industry especially in Asia
2. Identifying requirements and challenges in product development through clinical stages
3. Case study: Strategies for accelerating process development – balancing cost and quality, maximizing efficiency gains and enhancing innovation in the manufacturing process
He will also be participating in the below panel discussion:
Panel Discussion: Growth opportunities for biologics manufacturing industry in Asia: Will Asia complement or replace their western counterparts?
1. The opportunities and challenges in the biologics manufacturing space for Asia
2. Harmonizing the EMEA, FDA and SFDA requirements for facility design and driving down operational costs through disposable technology
3. Pharmas' and CMOs' perspective of the biologics manufacturing capabilities in Asia